Related references
Note: Only part of the references are listed.
Article
Dermatology
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders An Extension Study of 2 Randomized Clinical Trials
Jonathan I. Silverberg et al.
Summary: Baricitinib, a selective Janus kinase inhibitor, showed sustained long-term efficacy for patients with moderate to severe atopic dermatitis through 52 weeks of continuous therapy, improving clinical assessment scores and itch symptoms.
JAMA DERMATOLOGY (2021)
Article
Dermatology
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Article
Dermatology
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial
Kristian Reich et al.
JAMA DERMATOLOGY (2020)
Share Paper
